GSA Capital Partners’s Nautilus Biotechnolgy NAUT Stock Holding History

GSA Capital Partners’s Portfolio NAUT Stock Details NAUT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$189K	Buy	101,112 +46,413	+85%	+$123K	0.01%	1541
2026 Q1	$212K	Sell	54,699 -69,352	-56%	-$170K	0.01%	1430
2025 Q4	$242K	Sell	124,051 -135,152	-52%	-$222K	0.02%	1293
2025 Q3	$219K	Buy	259,203 +82,295	+47%	+$60.5K	0.02%	1382
2025 Q2	$128K	Buy	176,908 +164,396	+1,314%	+$124K	0.01%	1593
2025 Q1	$11K	Buy	+12,512	New	+$18.6K	﹤0.01%	1591
2023 Q1	–	Sell	-44,599	Closed	-$80K	–	1779
2022 Q4	$80K	Buy	44,599 +1,569	+4%	+$3.03K	0.01%	1326
2022 Q3	$91K	Buy	+43,030	New	+$108K	0.01%	1373

Other funds holding NAUT

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

ACM

AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

Cercano Management Bellevue, Washington $750M AUM 25.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CFM

Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return

GSA Capital Partners's NAUT Position: Q2 2026 in Review

GSA Capital Partners increased its Nautilus Biotechnolgy (NAUT) stake by 85% in Q2 2026, buying an estimated $123K and bringing the position to 101,112 shares worth $189K. The position accounts for 0.01% of the portfolio, ranked #1541.

GSA Capital Partners first reported a position in NAUT in Q3 2022 and has held it in 8 quarters since. The position peaked at $242K in Q4 2025. 93 funds tracked by Wall St. Rank hold NAUT as of Q2 2026.

GSA Capital Partners held 101,112 shares of Nautilus Biotechnolgy worth $189K as of Q2 2026.
GSA Capital Partners bought 46,413 Nautilus Biotechnolgy shares in Q2 2026, an estimated $123K.
Nautilus Biotechnolgy made up 0.01% of GSA Capital Partners's portfolio in Q2 2026, its #1541 holding.
GSA Capital Partners first reported a position in Nautilus Biotechnolgy in Q3 2022 and has held it in 8 quarters since.
GSA Capital Partners's Nautilus Biotechnolgy position peaked at $242K in Q4 2025.
93 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.